First-day Discharge Enhanced Recovery After Surgery Protocol for Minimal Invasive Colorectal Surgery
NCT ID: NCT06008834
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2023-10-01
2024-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose: the aim of this study is to evaluate an ERAS protocol with fist-day hospital discharge and domiciliary follow-up for minimal invasive colectomy.
Method: unicenter pilot study of patients with indication of minimally invasive right colectomy or sigmidectomy who will follow an ERAS protocol according to international guidelines and will be discharged the first day of surgery with a domiciliary follow-up. Hospital readmission is considered as the primary outcome. A total sample of 40 cases is considered, with 20 right colectomies and 20 sigmoidectomies. An independent analysis of both techniques will be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Economical Evaluation of Colorectal Surgery in Ambulatory Care
NCT03760939
ERAS in Colorectal Surgery: Benefits of Late Adoption
NCT05773248
Early Discharge After Robotic Colorectal Surgery (eRCS): a Prospective Observational Study
NCT05408182
Enhanced Recovery Program in Laparoscopic Colorectal Surgery: an Observational Controlled Trial
NCT04378465
Effects of Implementing an ERAS Protocol
NCT06010225
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Purpose: the aim of this study is to evaluate an ERAS protocol with fist-day hospital discharge and domiciliary follow-up for minimal invasive colectomy.
Method: unicenter pilot study of patients with indication of minimally invasive right colectomy or sigmidectomy who will follow an ERAS protocol according to international guidelines and will be discharged the first day of surgery with a domiciliary follow-up.
Outcomes:
* Primary: hospital readmission
* Secondary: postoperative complications (Clavien-Dindo), domiciliary follow-up mean time before final postoperative discharge, emergency department re-consulting.
Sample: a total sample of 40 cases is considered, with 20 right colectomies and 20 sigmoidectomies.
Analysis: an independent analysis of both techniques will be performed. Pilot study without control branch.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional group
Patients who undergo a minimal invasive colorectal surgery and are included in the first-day discharge protocol with domiciliary follow-up
First-day discharge protocol
Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
First-day discharge protocol
Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Benign or malignant desease.
* No expected stoma
* ASA ≤ III
* Family support
Exclusion Criteria
* Anticoagulant therapy
* Recent immunosupresor therapy (less than one month)
* Anemia (Male Hb \>120 g/L, Female Hb \>110 g/L)
* Malnutrition (Albumine \>35 g/L)
* Dementia
* Moderate or high frailty
* Syncronic neoplasia
* Previous colorectal surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corporacion Parc Tauli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Pallisera-Lloveras
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Pallisera-Lloveras, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Corporacio Parc Tauli. Parc Tauli University Hospital
Laura Mora-Lopez, MD, PhD
Role: STUDY_DIRECTOR
Corporacio Parc Tauli. Parc Tauli University Hospital
Oriol Pino-Perez, MD
Role: PRINCIPAL_INVESTIGATOR
Corporacio Parc Tauli. Parc Tauli University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parc Tauli University Hospital
Sabadell, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIR2022020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.